Comparative Cost-Effectiveness Analysis of Respiratory Syncytial Virus Vaccines for Older Adults in Hong Kong.

ABSTRACT: Two respiratory syncytial virus (RSV) vaccines (AREXVY^® and ABRYSVO^®) were recently approved for older adults in the US. This study aimed to evaluate the cost-effectiveness of AREXVY^® and ABRYSVO^® from the Hong Kong public healthcare provider's perspective. A two-year decision-analytical model was developed to examine the outcomes of a single RSV vaccination (AREXVY^® or ABRYSVO^®) compared to no vaccination. Primary outcomes included RSV-related health outcomes, direct medical costs, quality-adjusted life-year (QALY) loss, and incremental cost per QALY (ICER). RSV vaccines are not yet marketed in Hong Kong, base-case analysis, therefore, benchmarked US RSV vaccine prices at 4 levels (25%, 50%, 75%, 100%). AREXVY^® a

SUBMITTER: Wang Y 

PROVIDER: S-EPMC10610694 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature